✦ LIBER ✦

Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy

✍ Scribed by Manuela Zlamy; Johannes Hofer; Johannes Elias; Ulrich Vogel; Matthias Frosch; Therese Jungraithmayr; Lothar Bernd Zimmerhackl; Martina Prelog

Book ID: 115100052
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 270 KB
Volume: 16
Category: Article
ISSN: 1397-3142
DOI: 10.1111/j.1399-3046.2011.01585.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of eculizumab in a patient with

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

✍ Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 308 KB

Eculizumab therapy in an adult with plas

Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome

✍ Hallie C. Prescott; Haifeng M. Wu; Spero R. Cataland; Robert A. Baiocchi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 1 views

Interim analysis of phase II efficacy an

Interim analysis of phase II efficacy and safety data for eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion

✍ T.H.J. Goodship; P. Muus; C. Legendre; K. Douglas; M. Hourmant; Y. Delmas; M. He 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Safety and Long-Term Efficacy of Eculizu

Safety and Long-Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome

✍ V. Chatelet; V. Frémeaux-Bacchi; T. Lobbedez; M. Ficheux; B. Hurault de Ligny 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Influence of genotype on clinical charac

Influence of genotype on clinical characteristics of atypical hemolytic uremic syndrome (aHUS) with pediatric and adult onset

✍ V. Fremeaux-Bacchi; F. Fakhouri; A. Garnier; F. Bienaime; A.L. Sellier-Leclerc; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Eculizumab: Safety and Efficacy After 17

Eculizumab: Safety and Efficacy After 17 Months of Treatment in a Renal Transplant Patient With Recurrent Atypical Hemolytic-Uremic Syndrome: Case Report

✍ V. Châtelet; T. Lobbedez; V. Frémeaux-Bacchi; M. Ficheux; J.Ph. Ryckelynck; B. H 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 455 KB